Card is happy to announce that on February 19th, that we will be teaming up with Lineagen to offer an open house presentation and discussion on the benefits of genetic testing with individuals on the spectrum.
Center for Autism and Related Disorders (CARD) and Lineagen, Inc. today announced the launch of a new clinical partnership to offer Lineagen’s FirstStepDx® genetic test to patients and their families. FirstStepDx is a whole-genome genetic test customized with validated, novel proprietary genetic variants associated with ASDs. Under the terms of the partnership agreement, FirstStepDx, integrated with a pre-and post-test genetic counseling service and personalized reporting, will be offered to patients receiving treatment in CARD’s innovative Skills® program. The program is the first of its kind, designed to fully meet current clinical guidelines that recommend chromosomal microarray analysis as a first-line genetic test as part of a comprehensive diagnostic evaluation of individuals with ASDs.